Abstract
Revolizer® is a single dose dry powder inhaler (SDDPI) with moderate resistance, which requires a simple inhalation technique. We report here for the first-time results of Fluticasone/Formoterol (FF) (100/6 or 250/6 mcg; Maxiflo®) twice daily delivered by the Revolizer® on asthma control in patients with persistent asthma.This was a 24 weeks, prospective, non-comparative, multi-centre, open-label, real-world observational study. Patients participating in this study were either already on FF at any dose via Revolizer® or were uncontrolled on other treatment via Revolizer® and required a change in their treatment to FF, as per treating physicians' discretion. We assessed asthma control at baseline, Weeks 4, 8, 16 and 24 using Asthma Control Test™ (ACT). 401 patients were enrolled [mean age 41.1 ±14.36 years; 202 (50.37%) males] and 385 patients completed the study. At the end of 24 weeks asthma control was achieved in 80.78% of patients. Mean change in asthma control score from baseline to weeks 4, 8, 16 and 24 was 3, 3.8, 5.5 and 6.7, respectively (all p<0.0001). Day and night time symptoms reduced significantly (p<0.0001) over 24 weeks. Overall, FF was well tolerated, one patient was hospitalized. More than 98% patients found the Revolizer® easy to use. In a real world setting FF delivered via the Revolizer can achieve asthma control in majority of patients and is well tolerated.
- Copyright ©the authors 2016